SCHEDULE: Janus Henderson Group Discloses 12.3% Stake in Praxis Precision Medicines
Beneficial Ownership Report
Janus Henderson Group plc and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 12.3% in Praxis Precision Medicines, Inc. common stock as of September 30, 2025.
Summary
- Janus Henderson Group plc, a Jersey-based entity, reported beneficial ownership of 2,763,859 shares of Praxis Precision Medicines, Inc. common stock.
- This aggregate ownership represents 12.3% of the class of securities.
- Janus Henderson Biotech Innovation Master Fund Ltd, a Massachusetts-based entity, reported beneficial ownership of 1,379,790 shares, representing 6.2% of the class.
- This filing is an Amendment No. 3 to a previous Schedule 13G, indicating an update to their existing position.
- The beneficial ownership was determined as of September 30, 2025.
- The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The filing indicates a significant and continued institutional stake by Janus Henderson Group in Praxis Precision Medicines, which can be viewed as a vote of confidence. However, as an amendment, it primarily updates an existing position rather than signaling a new investment thesis or a change in company fundamentals.
Future Outlook
NA
Industry Context
This filing provides transparency regarding significant institutional ownership in Praxis Precision Medicines, a common practice in the biotech and pharmaceutical sectors where institutional investors often hold substantial stakes due to the high-risk, high-reward nature of drug development.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
- Company Management: Awareness of a large institutional holder may influence strategic decisions, though the filing states the holding is not for control purposes.
Key Dates
| Date | Description |
|---|---|
| 2022-12-09 | Date Power of Attorney was executed by Janus Henderson Group plc. |
| 2025-09-30 | Date of event which requires filing of this statement, reflecting the beneficial ownership. |
| 2025-11-14 | Date of filing and signature by Kristin Mariani. |
Keywords
Praxis Precision Medicines, Janus Henderson Group, beneficial ownership, Schedule 13G, common stock, institutional investment, biotech, pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.